Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
29048 | 158 | 28.3 | 37% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CHIMERIC ANTIBODY 311 | Author keyword | 1 | 50% | 1% | 1 |
2 | COLON CANCER ANTIGENS | Author keyword | 1 | 50% | 1% | 1 |
3 | HJ TAGNON | Address | 1 | 50% | 1% | 1 |
4 | LONG WAVE FLUORESCENCE | Author keyword | 1 | 50% | 1% | 1 |
5 | LS174T XENOGRAFTS | Author keyword | 1 | 50% | 1% | 1 |
6 | PANCREATIC AND COLON CANCER | Author keyword | 1 | 50% | 1% | 1 |
7 | STOOL ELISA | Author keyword | 1 | 50% | 1% | 1 |
8 | RECRUITMENT EFFECTIVENESS | Author keyword | 0 | 33% | 1% | 1 |
9 | CLINICAL TRIAL EFFICIENCY | Author keyword | 0 | 25% | 1% | 1 |
10 | TECHNOL STORAGE | Address | 0 | 25% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TAA | 2 | 50% | 2% | 3 |
2 | KILLED EX VIVO | 0 | 33% | 1% | 1 |
3 | LEUKOTAXIS | 0 | 33% | 1% | 1 |
4 | FILAMENT AUTOANTIBODIES | 0 | 25% | 1% | 1 |
5 | IRRADIATED TUMOR CELLS | 0 | 17% | 1% | 1 |
6 | PREEXISTING MURINE TUMORS | 0 | 17% | 1% | 1 |
7 | FACTOR INACTIVATORS | 0 | 100% | 1% | 1 |
8 | INOSITOLPHOSPHOCERAMIDE | 0 | 100% | 1% | 1 |
9 | RADIATION INDUCED CANCERS | 0 | 100% | 1% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
The Use of Specific Monoclonal Antibodies to Target Immunogenic Tumor Membrane Proteins in Patients with Recurrent Pancreatic and Colon Cancer | 2012 | 3 | 11 | 27% |
Optimizing the Immune System to Achieve Control of the Metastatic Malignant Lesion | 2013 | 0 | 14 | 29% |
Science, medicine, and the future - Lung cancer | 1997 | 7 | 7 | 14% |
The Therapeutic Value of Monoclonal Antibodies Directed Against Immunogenic Tumor Glycoproteins | 2010 | 1 | 18 | 11% |
Cost-effectiveness of health research study participant recruitment strategies: A systematic review | 2014 | 0 | 23 | 13% |
Active, specific immunotherapy for lung cancer: Hurdles and strategies using genetic modification | 2003 | 1 | 70 | 6% |
ARE CORYNEBACTERIA STIMULATORS OF ANTITUMOUR RESISTANCE | 1984 | 0 | 14 | 43% |
Immune responses in broncho-pulmonary cancer | 2003 | 0 | 99 | 7% |
TUMOR IMMUNOLOGY - A REVIEW | 1984 | 4 | 9 | 11% |
NATURAL-HISTORY OF LUNG-CANCER | 1982 | 10 | 22 | 9% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | HJ TAGNON | 1 | 50% | 0.6% | 1 |
2 | TECHNOL STORAGE | 0 | 25% | 0.6% | 1 |
3 | INVEST CLIN ONCOL EXPT | 0 | 14% | 0.6% | 1 |
4 | UCD LIFE SCI | 0 | 13% | 0.6% | 1 |
5 | MHS | 0 | 10% | 0.6% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000123903 | FC 215//ACUTE HYPERSENSITIVITY PNEUMONITIS//HUMAN ANTIMURINE ANTIBODY |
2 | 0.0000117646 | TOXOPLASMA LYSATE ANTIGEN//OBIOPEPTIDE//L5178Y R LYMPHOMA |
3 | 0.0000106463 | LEVAMISOLE//AMINOREX//4 METHYLAMINOREX |
4 | 0.0000090595 | MED CHILDRENS HOSP FDN//PEDIAT SURG 219 BRYANT ST//PESQUISA SOBRE TIMO |
5 | 0.0000089601 | CARDIOMYOPATHY DILATED MYOCARDITIS//LYMPHOCYTES FUNCTION INTRACELLULAR METABOLISM// |
6 | 0.0000081269 | VIRAL ONCOLYSATE//CELLULAR IMMUNOL D010//MTH 68 H |
7 | 0.0000079465 | BELAGENPUMATUCEL L//SRL172//PA MSHA |
8 | 0.0000077672 | TRANSPLACENTAL MUTAGENICITY//ANTITUMOR PREPARATIONS//CANA3DTPA |
9 | 0.0000071191 | COLD TARGET COMPETITION//COMPLEMENT DISTRIBUTION//DEFORMABILITY OF RED CELLS |
10 | 0.0000065859 | TL 2 RESPONSE//ADCC REACTION//ANTI IG DEXTRAN |